Peddock Capital Advisors LLC Increases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Peddock Capital Advisors LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 20,806 shares of the biopharmaceutical company’s stock after acquiring an additional 338 shares during the period. Peddock Capital Advisors LLC’s holdings in Gilead Sciences were worth $1,685,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of GILD. Charles Schwab Investment Management Inc. raised its stake in shares of Gilead Sciences by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock valued at $589,873,000 after acquiring an additional 87,482 shares during the period. Northern Financial Advisors Inc boosted its position in shares of Gilead Sciences by 17.3% in the fourth quarter. Northern Financial Advisors Inc now owns 4,008 shares of the biopharmaceutical company’s stock worth $325,000 after buying an additional 592 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in shares of Gilead Sciences by 7.5% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 99,536 shares of the biopharmaceutical company’s stock valued at $8,063,000 after buying an additional 6,980 shares in the last quarter. Apollon Wealth Management LLC raised its holdings in shares of Gilead Sciences by 111.2% during the 4th quarter. Apollon Wealth Management LLC now owns 35,027 shares of the biopharmaceutical company’s stock valued at $2,838,000 after buying an additional 18,444 shares during the period. Finally, Lincoln National Corp lifted its position in Gilead Sciences by 42.1% during the 4th quarter. Lincoln National Corp now owns 12,778 shares of the biopharmaceutical company’s stock worth $1,035,000 after acquiring an additional 3,785 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of a number of analyst reports. UBS Group dropped their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Barclays cut their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a report on Monday, April 29th. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price for the company in a research note on Wednesday, April 24th. Cantor Fitzgerald cut their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. Finally, Morgan Stanley lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Stock Down 0.7 %

Shares of GILD stock traded down $0.45 on Wednesday, reaching $65.01. 2,341,495 shares of the company’s stock traded hands, compared to its average volume of 7,396,560. Gilead Sciences, Inc. has a 12-month low of $64.33 and a 12-month high of $87.86. The company has a market capitalization of $80.94 billion, a P/E ratio of 181.83, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. The business’s 50 day moving average price is $70.25 and its two-hundred day moving average price is $75.60.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. During the same period last year, the company earned $1.37 earnings per share. Gilead Sciences’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, equities analysts forecast that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.74%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.